The long data timeline (H2 2029) limits near-term catalysts, but the deal expands Tarsus' retina pipeline with a potentially blockbuster orphan drug. Watch for HSR clearance and any competitive Stargardt pipeline updates; near-term stock movement likely driven by financing details and investor reception of the upfront cash/stock mix.
Price Chart
Executive Summary
Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001). The deal weds a promising but early-stage asset with no approved therapy today against Tarsus' existing retina capabilities, and top-line data is not expected until H2 2029. The acquisition is accretive to Tarsus' pipeline but adds significant execution risk and a long timeline.
Key Financial Metrics
Key Facts
- Upfront consideration: ~$450 million ($270M cash + $180M Tarsus common stock at $61.38/share).
- Milestones: up to $350 million upon regulatory approval and first commercial sale.
- Royalties: low single-digit tiered descending on gildeuretinol net sales.
- Phase 3 NORTHSTAR trial (enrolling ~230 patients) topline data expected H2 2029.
- Stargardt disease has ~36,000 clinically diagnosed patients in the U.S. with no FDA-approved therapy.
- Gildeuretinol has Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.
- TEASE-1 data: 29.5% slower annualized growth rate of atrophic lesions (p<0.001) vs untreated arm; 87% less likely to experience significant low-light vision loss.
- Transaction approved by both boards and Alkeus stockholders; expected to close in 2026.
- Tarsus' pipeline includes XDEMVY (approved), TP-04 (Phase 2), TP-05 (Phase 2), and IRX-101 (Phase 2).
Financial Impact
$450M upfront plus up to $350M in regulatory/milestone payments; low single-digit royalties on net sales
Risk Factors
- Phase 3 failure risk (Stargardt trials are notoriously difficult to read on endpoints)
- Dilution from ~$180M stock issuance (2.93M shares at $61.38, ~6% of current shares outstanding if pre-money ~48M shares)
- Long timeline (H2 2029) with no near-term revenue from gildeuretinol
- Integration risk and cash burn ($270M upfront depletes Tarsus' cash reserves)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $82.77 $77.64 | ▼ −6.20% | ▼ −5.54% | $73.61 (−11.06%) |
Sep 3, 2026 29d ago | Insider Cluster | $83.21 $79.31 | ▼ −4.68% | ▼ −3.53% | $73.61 (−11.53%) |
Sep 2, 2026 29d ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Sep 1, 2026 4w ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Aug 19, 2026 6w ago | 144 | $73.44 $70.65 | ▼ −3.80% | ▼ −3.41% | $73.61 (+0.24%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access